CD11B/Integrin Alpha M Polyclonal antibody

CD11B/Integrin Alpha M Polyclonal Antibody for ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 20991-1-AP

Synonyms

CD11B, CR 3 alpha chain, CR3A, Integrin alpha M, ITGAM, MAC 1, MAC1A, MO1A, Neutrophil adherence receptor, SLEB6



Tested Applications

Recommended dilution

ApplicationDilution
Sample-dependent, check data in validation data gallery

Product Information

20991-1-AP targets CD11B/Integrin Alpha M in WB, IHC, IF, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Peptide 相同性解析による交差性が予測される生物種
Full Name integrin, alpha M (complement component 3 receptor 3 subunit)
Calculated molecular weight 93 kDa
Observed molecular weight 110-170 kDa
GenBank accession numberNM_000632
Gene symbol ITGAM
Gene ID (NCBI) 3684
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Integrins are cell adhesion receptors that are heterodimers composed of non-covalently associated α and β subunits (PMID: 9779984). CD11b, also known as Integrin alpha M or CR3A, belongs to the integrin alpha chain family. CD11b forms an α/β heterodimer with CD18 (integrin β2). CD11b/CD18 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens (PMID: 9558116; 20008295). CD11b/CD18 is a receptor for the complement protein fragment iC3b, and is also a receptor for fibrinogen, factor X and ICAM1 (PMID: 2971974; 15485828).

Protocols

Product Specific Protocols
IHC protocol for CD11B/Integrin Alpha M antibody 20991-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
IHC

J Nanobiotechnology

Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells

Authors - Hua‑Zhen Xu
humanIHC

Cancer Lett

Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.

Authors - Xiong Zhang
humanWB

Cancer Immunol Immunother

Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas.

Authors - Pei Yang
IF

J Nanobiotechnology

Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.

Authors - Shen-Jun Yuan
IHC

Neuropharmacology

Trans-cinnamaldehyde improves memory impairment by blocking microglial activation through the destabilization of iNOS mRNA in mice challenged with lipopolysaccharide.

Authors - Liqing Zhang
WB,IHC

Mol Neurobiol

Myeloid TBK1 Deficiency Induces Motor Deficits and Axon Degeneration Through Inflammatory Cell Infiltration.

Authors - Weisong Duan